What is TAKHZYRO?
TAKHZYRO is the #1 prescribed HAE preventive treatment.
Based on total patients on HAE preventive treatments according to US third-party industry healthcare data.
Soraya
Real TAKHZYRO patient.
4000+ PEOPLE IN THE U.S. PRESCRIBED* SINCE 2018
after talking to their doctors
FEWER ATTACKS OR ZERO ATTACKS IN 2 CLINICAL STUDIES
A 6.5-month clinical trial and a 2.5-year open-label extension study†
≤1 MINUTE TO INJECT
for most people in the clinical studies‡
Most adolescents and adults in the clinical studies self administered TAKHZYRO within 10 to 60 seconds. These injection times are based on vial administration. Please see TAKHZYRO Dosing and Administration for further information.
*Based on 3rd party US specialty pharmacy data.
†The 6.5-month clinical study included 125 people diagnosed with HAE aged 12 years and older. The main goal of the study was to evaluate the ability of TAKHZYRO 300 mg every 2 weeks to reduce the frequency of HAE attacks. On average, people had 87% fewer attacks compared to placebo. 44% of people had zero attacks for the entire 6.5-month study compared to 2% of those taking placebo. The 2.5-year open-label extension study included 212 people diagnosed with HAE aged 12 years and older. The main goal of this study was to evaluate the long-term safety of TAKHZYRO 300 mg every 2 weeks. Patients knew they were receiving TAKHZYRO, which could have influenced the study results. In this study, people taking TAKHZYRO for an average of 2.5 years had similar results to those in the 6.5-month clinical study. On average, people had 87% fewer attacks compared with baseline. ~69% of people had zero attacks for up to a year.
‡For people 12 years of age and older taking TAKHZYRO. In clinical studies, the majority of patients self-administered TAKHZYRO over 10 to 60 seconds. These injection times are based on vial administration.
The recommended dose is 300 mg every 2 weeks for people starting on TAKHZYRO.
If you have zero attacks for more than 6 months, your doctor may consider prescribing TAKHZYRO 300 mg once every 4 weeks.
SELECT IMPORTANT SAFETY INFORMATION
TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms:
- wheezing
- difficulty breathing
- chest tightness
- fast heartbeat
- faintness
- rash
- hives
TAKHZYRO has been approved since 2018 and has been prescribed to over 4000 adolescents and adults*
See how these real people with HAE are choosing to reimagine their lives with TAKHZYRO. Individual results may vary.
*Based on third-party US specialty pharmacy data.
Andrew
After a lifelong struggle with HAE, Andrew’s doctor got him into a clinical trial for what would later be called TAKHZYRO. Now, he’s been taking it for more than eight years. Listen to his full story.
Escuchar en Español.
ANDREW: Growing up with HAE was not fun. I guess that's an understatement. I was having attacks as a kid, and no one knew what was causing them or how to treat them. The best I could do was wait for the swells to go down on their own.
We did notice certain patterns in my attacks. I would often get an attack if I was dehydrated. It's not a secret that Arizona can get pretty hot. I'm a kid, so I'm running around playing football with my friends at school, not drinking any water. I'd come in, get dehydrated, and have an attack. Next thing I know, I'm going home. But of course, I'm not going to stop playing with my friends, so this kept happening.
My mom is a nurse. She kept pushing to find out what was wrong. I really have her to thank for even getting me diagnosed with HAE. When I went away to college, my HAE got worse. Stress caused me to have attacks and college, at least for me, was pretty stressful. Late nights, cramming, writing papers, always doing whatever I could to manage those situations, and prevent that next attack.
In 2016, my doctor told me about a clinical study for a preventive treatment that would eventually become TAKHZYRO. He said it was a subcutaneous injection that I would take once every two weeks, and it had the potential to actually help reduce the frequency of my attacks.
After TAKHZYRO was approved, my doctor and I decided that I would stay on therapy. He mentioned serious side effects, including allergic reactions, and some of the more common side effects, like injection site reactions, upper respiratory infections, and headaches.
I was willing to give it a try, and it has definitely worked out for me. I have fewer HAE attacks. The ones I do have are less severe, too. All totaled, I've been on it eight years.
Since then, I've kept working, got married, and had two kids. I still have breakthrough attacks from time to time, but they're pretty rare. I've even gone up to a year without an attack. It's hard to live a stress-free life, but I don't work as hard to actively manage my stress as I used to.
Not too long ago though, we were traveling with the kids. Oldest one was three. It was very stressful, and on the plane, I had an attack. It was minor, but I still took my acute medication, and the attack had cleared up by the next day.
Every now and then, stress will sneak up on you. I'm reminded that I still have HAE, but I still have TAKHZYRO, and TAKHZYRO definitely helps me manage my HAE attacks proactively, so I'm grateful for it.
NARRATOR: What is TAKHZYRO? TAKHZYRO® (lanadelumab) is a prescription medicine used to prevent attacks of hereditary angioedema (HAE) in people 2 years of age and older. It is not known if TAKHZYRO is safe and effective in children under 2 years of age.
Important Safety Information. TAKHZYRO may cause serious side effects, including allergic reactions. Call your healthcare provider or get emergency help right away if you have any of the following symptoms: wheezing, difficulty breathing, chest tightness, fast heartbeat, faintness, rash, hives.
The most common side effects seen with TAKHZYRO were injection site reactions (pain, redness, and bruising), upper respiratory infection, headache, rash, dizziness, diarrhea, and muscle aches. These are not all the possible side effects of TAKHZYRO. For more information, ask your healthcare provider or pharmacist. You may report side effects to FDA at 1-800-FDA-1088.
TAKHZYRO has not been studied in pregnant or breastfeeding women. Talk to your healthcare provider about the risk of taking TAKHZYRO if you are pregnant, plan to be pregnant, are breastfeeding, or plan to breastfeed.
Please see full Prescribing Information, including information for patients, at TAKHZYRO.com.